摘要
目的采用体外培养的肿瘤细胞系探讨甲胎蛋白特异启动元件介导的靶向性肝癌基因治疗。方法将2.2kb的重组人甲胎蛋白(AFP)基因顺式调控元件克隆于胞嘧啶脱氨酶(CD)基因的上游,构建逆转录病毒载体LX2.2CD。再以此载体和另一不含AFP基因调控元件的逆转录病毒载体pCD2分别转染3种肝癌细胞系和1种肺腺癌细胞系,筛选出整合CD基因的抗G418克隆,并进行细胞生长抑制实验。结果5氟胞嘧啶(5FC)对用LX2.2CD转染的AFP阳性肝癌细胞具有特异杀伤作用,而对AFP阴性的肝癌细胞和非肝癌细胞无杀伤作用。结论在细胞水平实现了对AFP阳性肝癌细胞的靶向性基因治疗。
Objective To investigate the α fetoprotein (AFP) specific promoter mediated target gene therapy of hepatocellular carcinoma in vitro. Methods Retroviral vector (LX2.2CD) in which the cytosine deaminase (CD) gene was driven by the 2.2 kb recombinant human AFP TRS. After transfecting three human hepatoma cell lines and one non hepatoma cell line with LX2.2 CD, anti G418 clones integrated CD gene were selected, and inhibitory experiment of cell growth was performed.Results 5 fluorocytosine (5FC) could confer the chemosensitivity to transduced AFP producing hepatoma cells (HuH 7 and huH 1/c1 2), but not to AFP nonproducing hepatoma cells (HLE) or nonhepatoma cells (GLC). On the other hand, when transfecting the above four tumor cell lines with another retroviral vector pCD2 (CD gene was driven by 5′LTR internal promoter), no cell selection was found in 5FC induced cell grow inhibition.Conclusions Recombinant retrovival transfer of the CD gene under the control of the AFP TRS followed by 5FC may well be a promising targeted gene therapy for hepatoma.
出处
《中国医学科学院学报》
CAS
CSCD
北大核心
1999年第2期111-117,共7页
Acta Academiae Medicinae Sinicae
基金
国家教委博士点基金
林孟熹医学基金